Clinical Trial Update: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) [Phase 3]

View source ↗

Summary

A Phase 3 study (SERENA-6) is evaluating AZD9833 plus a CDK4/6 inhibitor in HR+/HER2-negative breast cancer with ESR1 mutation; the trial is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• AZD9833 (AZD9833)
• CDK4/6 inhibitor

Snippet

Sponsor: AstraZeneca | Conditions: ER-Positive HER2-Negative Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING